Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® in metastatic uveal melanoma
Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting
Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI - its first tissue-specific autoimmune candidate - for patients with type 1 diabetes
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® in previously treated advanced melanoma
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting
Immunocore reports fourth quarter and full year 2025 financial results and provides a business update
Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025
Cerrado Gold Acquires the Past-Producing Manantial Espejo Mine in Santa Cruz, Argentina, from Pan American Silver
Triumph Gold Announces Strategic Review of Non-Core Exploration Projects and $15 Million Private Placement
